Naveruclif (Paclitaxel)

Paclitaxel stabilizes microtubules by binding to β‑tubulin, preventing their depolymerisation. This blocks the normal formation of the mitotic spindle, halting cell division at the G2/M phase and leading to apoptosis of rapidly dividing cancer cells.

The dosing regimen for Naveruclif is determined by the prescribing oncologist based on the specific cancer type, patient weight, treatment protocol and clinical response. Exact dose and schedule should be individualized and are not disclosed publicly.

Paclitaxel is classified as contraindicated in pregnancy because it can cause fetal harm. Women who are pregnant, planning to become pregnant, or breastfeeding should not receive Naveruclif unless the potential benefit justifies the risk and a specialist advises otherwise.

To request Naveruclif, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Naveruclif (paclitaxel) belongs to the taxane class, similar to docetaxel. Both agents stabilize microtubules, but paclitaxel has a distinct pharmacokinetic profile and may require different pre‑medication strategies. Choice between them depends on tumour type, prior therapy, tolerance, and physician preference.

Naveruclif should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until preparation for infusion to maintain stability.

Naveruclif is given by intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are defined by the treatment protocol, and patients are monitored for infusion‑related reactions throughout the administration.

Serious risks include severe hypersensitivity reactions (including anaphylaxis), febrile neutropenia, pulmonary toxicity, and significant mucositis. Prompt recognition and management of these events are essential, and patients should be closely monitored during and after infusion.

Patients with a known hypersensitivity to paclitaxel or other taxanes, those with severe uncontrolled infections, or individuals with significant hepatic impairment that cannot be managed should avoid Naveruclif. The prescribing clinician must evaluate each case for contraindications.